Merck-Glenmark Januvia mediation efforts flop
This article was originally published in Scrip
Executive Summary
Mediation efforts in the high profile patent infringement litigation concerning Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride) appear to have failed, setting the stage for a crucial verdict in the case potentially early 2015.